Market Place
Sourcing Support
Noema Pharma Closes CHF 130M in Series B Financing Round
11 Dec 2024 //
BUSINESSWIRE
EQT Funds CHF 130M For Noema Pharma Series B Extension
11 Dec 2024 //
PR NEWSWIRE
Noema Pharma Doses First Patients in Phase 2b Tourette Study
30 Oct 2024 //
GLOBENEWSWIRE
Noema’s NOE-105 Study In Tourette Syndrome Meets All Endpoints
17 Oct 2024 //
GLOBENEWSWIRE
Noema ticks off phase 2a Tourette win for ex-Roche molecule
17 Oct 2024 //
FIERCE BIOTECH
Noema Pharma Completes Enrollment For GALENE Phase 2B Trial Of NOE-101
13 Aug 2024 //
GLOBENEWSWIRE
Noema Pharma Doses First Patient In NOE-115 Menopause Study
22 May 2024 //
GLOBENEWSWIRE
Noema Pharma to Present at Two Upcoming Conferences
03 Jan 2024 //
GLOBENEWSWIRE
Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer
21 Jun 2023 //
GLOBENEWSWIRE
Noema Pharma to Present at BioEquity Europe 2023
09 May 2023 //
GLOBENEWSWIRE
Noema Pharma Raises CHF 103 Million in Series B Financing
07 Mar 2023 //
BUSINESSWIRE
Noema Pharma Raises CHF 103 Million in Series B Financing Round
07 Mar 2023 //
GLOBENEWSWIRE
Noema Pharma to Attend and Present at 41st J.P. Morgan Conference
05 Jan 2023 //
GLOBENEWSWIRE
Noema Pharma Receives FDA Fast Track Designation for basimglurant
18 Oct 2022 //
GLOBENEWSWIRE
Noema Pharma Announces Completion of Enrollment in the (TNED) Validation Study
06 Sep 2022 //
GLOBENEWSWIRE
Noema Pharma Recruits First Patient in Orpheus Phase 2b Study of PDE10A
04 Aug 2022 //
GLOBENEWSWIRE
Noema Pharma Announces FDA IND Authorization for Orpheus PIIb Study of NOE-105
27 Jun 2022 //
GLOBENEWSWIRE
Noema Pharma to Attend and Present at BioEquity Europe and UBS Global Conference
06 May 2022 //
GLOBENEWSWIRE
Noema Pharma to Attend and Present at Stifel 2022 CNS Days
25 Mar 2022 //
GLOBENEWSWIRE
Noema Pharma Appoints Michael Gutch as Chief Financial Officer
28 Feb 2022 //
GLOBENEWSWIRE
Noema to publish “Noema, Basimglurant & New Trial for Seizures in TSC” podcast
21 Feb 2022 //
PRESS RELEASE
FDA Clears IND for Noema Pharma`s Phase 2b LibraTN Study of NOE-101
14 Feb 2022 //
GLOBENEWSWIRE
Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105
05 Aug 2021 //
GLOBENEWSWIRE
Valneva Announces Positive Phase 3 Pivotal Results for its Chikungunya Vaccine
05 Aug 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.